<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="308">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157139</url>
  </required_header>
  <id_info>
    <org_study_id>0106922</org_study_id>
    <nct_id>NCT05157139</nct_id>
  </id_info>
  <brief_title>Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease</brief_title>
  <official_title>Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assoc. Prof. Ayman Baeis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Noha Alaa Eldine Hassan Hamdy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ph. Hanya Hesham Sweilam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The study is a randomized clinical trial to assess a natural formula of vanillin &amp; wheat&#xD;
           germ oil to treat and stop the clinical progression of COVID-19.&#xD;
&#xD;
        -  The study aims to treat people with mild-to-moderate COVID-19 before their cases become&#xD;
           severe.&#xD;
&#xD;
        -  The study duration is a 5-day experimental intervention and an extended 4 weeks follow&#xD;
           up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Mean change in the disease severity (clinical assessment).</measure>
    <time_frame>3-5 days</time_frame>
    <description>Time taken for the changes from moderate or mild or complete recovery/FDA assessment of key COVID-19-related symptoms score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Rate of disease remission.</measure>
    <time_frame>3-5 days</time_frame>
    <description>For mild/moderate symptoms patients: fever, cough and other symptoms relieved</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Hospitaization &amp; Survival rate</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Comparing the influence of the intervention on the hospitalization &amp; Survival rate followed for up to 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>4. Mean change in complete blood picture</measure>
    <time_frame>3-5 days</time_frame>
    <description>CBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5. Mean change in C reactive protein (CRP)</measure>
    <time_frame>3-5 days</time_frame>
    <description>CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9. The mean change in serum interleukin-6 (IL-6)</measure>
    <time_frame>3-5 days</time_frame>
    <description>serum IL-6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Mild-to-moderate COVID-19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving only standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention (low dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two capsules twice daily for 3 days then one capsule twice daily for 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention (high dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two capsules three times daily for 3 days, followed by one capsule three times daily for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Capsule</intervention_name>
    <description>Oral Capsule of vanillin &amp; wheat germ oil</description>
    <arm_group_label>Intervention (high dose)</arm_group_label>
    <arm_group_label>Intervention (low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PCR confirmed diagnosis for COVID-19.&#xD;
&#xD;
          2. Age â‰¥18 years.&#xD;
&#xD;
          3. Both genders&#xD;
&#xD;
          4. The disease started within 7 days (ideally 72 hours) of diagnosis or clinical&#xD;
             deterioration.&#xD;
&#xD;
          5. Patients diagnosed as mild or moderate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with severe Illness: Individuals who have SpO2 &lt;92% on room air at&#xD;
             sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired&#xD;
             oxygen (PaO2/FiO2) &lt;300 mm Hg, respiratory frequency &gt;30 breaths/min, or lung&#xD;
             infiltrates &gt;50%.&#xD;
&#xD;
          2. General: advanced kidney disease; advanced liver disease; pregnancy (known or&#xD;
             potential) or lactation, and advanced cardiovascular diseases.&#xD;
&#xD;
          3. Allergy to Vanilla flavor, vanillin, or wheat germ oil&#xD;
&#xD;
          4. Active cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <zip>21521</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed I ElMallah, PhD</last_name>
      <phone>+201001708794</phone>
      <email>ahmed.elmallah@alexu.edu.eg]</email>
    </contact>
    <investigator>
      <last_name>Ayman I Baess, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noha A Hamdy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanya H Sweilam, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 10, 2021</study_first_submitted>
  <study_first_submitted_qc>December 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 10, 2021</last_update_submitted>
  <last_update_submitted_qc>December 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Ahmed Ibrahim ElMallah</investigator_full_name>
    <investigator_title>Professor of Pharmacology &amp; Therapeutics, Faculty of Pharmacy, Alexandria University</investigator_title>
  </responsible_party>
  <keyword>mild-to-moderate COVID-19 vanillin, wheat germ oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The research team will share after results</ipd_description>
    <ipd_time_frame>up to March 2022</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

